150 related articles for article (PubMed ID: 10960842)
1. Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes.
del Vecchio MT; Tripodi SA; Arcuri F; Pergola L; Hako L; Vatti R; Cintorino M
Prostate; 2000 Sep; 45(1):51-7. PubMed ID: 10960842
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
[TBL] [Abstract][Full Text] [Related]
3. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
Wang X; Qi M; Zhang J; Sun X; Guo H; Pang Y; Zhang Q; Chen X; Zhang R; Liu Z; Liu L; Hao X; Han B
Prostate; 2019 May; 79(7):709-719. PubMed ID: 30825345
[TBL] [Abstract][Full Text] [Related]
4. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.
Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F
Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398
[TBL] [Abstract][Full Text] [Related]
6. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Montironi R; Magi-Galluzzi C; Muzzonigro G; Prete E; Polito M; Fabris G
J Clin Pathol; 1994 Oct; 47(10):906-13. PubMed ID: 7525657
[TBL] [Abstract][Full Text] [Related]
7. Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia.
Wheeler TM
Eur Urol; 1996; 30(2):261-4. PubMed ID: 8875209
[TBL] [Abstract][Full Text] [Related]
8. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
Tran TA; Jennings TA; Ross JS; Nazeer T
Am J Surg Pathol; 1998 Mar; 22(3):347-54. PubMed ID: 9500777
[TBL] [Abstract][Full Text] [Related]
9. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.
Meyer-Siegler KL; Iczkowski KA; Vera PL
BMC Cancer; 2005 Jul; 5():73. PubMed ID: 16000172
[TBL] [Abstract][Full Text] [Related]
10. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
Têtu B
Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
[No Abstract] [Full Text] [Related]
12. Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis.
Ambrosio MR; Rocca BJ; Barone A; Ginori A; Crivelli F; Pirtoli L; Del Vecchio MT
Anticancer Res; 2015 Oct; 35(10):5595-600. PubMed ID: 26408731
[TBL] [Abstract][Full Text] [Related]
13. Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and treatment-related changes.
Rocca BJ; Ginori A; Barone A; Calandra C; Crivelli F; De Falco G; Gazaneo S; Tripodi S; Cevenini G; del Vecchio MT; Ambrosio MR; Tosi P
Biomed Res Int; 2015; 2015():985950. PubMed ID: 25667934
[TBL] [Abstract][Full Text] [Related]
14. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
[TBL] [Abstract][Full Text] [Related]
15. The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
Helpap B
Virchows Arch; 2006 Apr; 448(4):480-4. PubMed ID: 16506014
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
17. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
[TBL] [Abstract][Full Text] [Related]
18. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
Leibowitz RL; Tucker SJ
Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
[TBL] [Abstract][Full Text] [Related]
19. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
20. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung.
Kamimura A; Kamachi M; Nishihira J; Ogura S; Isobe H; Dosaka-Akita H; Ogata A; Shindoh M; Ohbuchi T; Kawakami Y
Cancer; 2000 Jul; 89(2):334-41. PubMed ID: 10918163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
